A001360 Stock Overview
Manufactures and sells pharmaceutical products in South Korea. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
SAMSUNG PHARM. Co., LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩1,586.00 |
52 Week High | ₩2,705.00 |
52 Week Low | ₩1,450.00 |
Beta | 0 |
11 Month Change | 0.57% |
3 Month Change | -2.58% |
1 Year Change | -31.64% |
33 Year Change | -67.89% |
5 Year Change | -65.41% |
Change since IPO | -87.36% |
Recent News & Updates
Recent updates
Shareholder Returns
A001360 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 4.5% | -0.9% | 0.9% |
1Y | -31.6% | 7.7% | -3.4% |
Return vs Industry: A001360 underperformed the KR Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: A001360 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
A001360 volatility | |
---|---|
A001360 Average Weekly Movement | 7.5% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in KR Market | 11.6% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A001360 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A001360's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1929 | n/a | Won-Kyu Kim | www.sspharm.co.kr |
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others.
SAMSUNG PHARM. Co., LTD. Fundamentals Summary
A001360 fundamental statistics | |
---|---|
Market cap | ₩142.97b |
Earnings (TTM) | -₩5.96b |
Revenue (TTM) | ₩44.65b |
0.0x
P/S Ratio0.0x
P/E RatioIs A001360 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A001360 income statement (TTM) | |
---|---|
Revenue | ₩44.65b |
Cost of Revenue | ₩36.63b |
Gross Profit | ₩8.02b |
Other Expenses | ₩13.98b |
Earnings | -₩5.96b |
Last Reported Earnings
Sep 30, 2019
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A001360 perform over the long term?
See historical performance and comparison